BLVRB

BLVRB is an NADPH-dependent biliverdin IXβ reductase that functions as a cytoprotective redox enzyme governing the balance between erythroid and megakaryocyte lineage commitment in hematopoiesis (PMID:27207795, PMID:33359909). Its active site engages flavin and biliverdin IXβ tetrapyrrole substrates within an α/β dinucleotide NAD(P)H-binding fold, and the loss-of-function S111L mutation abolishes this redox activity, causing reactive oxygen species accumulation that drives exaggerated megakaryocytopoiesis and thrombopoiesis (PMID:27207795). Genetic ablation in mice establishes that BLVRB is dispensable for steady-state hematopoiesis but is required during stress hematopoiesis, where its absence produces defective stress erythropoiesis, megakaryocyte-biased recovery, and defective lipid peroxidation indicative of oxidant mishandling (PMID:33359909). Active-site binding has been resolved by NMR and co-crystallography, and small-molecule inhibitors of this site promote megakaryocyte speciation and expand platelet recovery in vivo, positioning BLVRB as a druggable node in thrombopoiesis (PMID:40216753). In red blood cells BLVRB additionally forms an oxygen-sensitive complex with the N-terminal cytosolic domain of Band 3 (SLC4A1) at normoxia that dissociates under hypoxia, and BLVRB Cys109 relays nitric oxide to trans-nitrosate GAPDH at Cys152 to inhibit glycolysis, coordinating redox and glycolytic remodeling during hypoxic adaptation (PMID:42224377).

1. 1995 Medium

   Establishing the genomic location of BLVRB was the first step toward defining it as a discrete human gene amenable to functional and genetic study.

   Evidence FISH mapping using a liver cDNA fragment

   PMID:7656592

   Open questions at the time

   • No functional or enzymatic role assigned
   • No tissue expression or phenotype linkage
   • Single method, single lab
2. 2016 High

   Identifying BLVRB as an NADPH-dependent biliverdin IXβ reductase and linking its loss-of-function S111L mutation to ROS-driven thrombopoiesis converted a mapped gene into a defined redox enzyme controlling megakaryocyte output.

   Evidence Platelet transcriptome sequencing, thrombocytosis cohort analysis, and in vitro redox assays with BLVRB(S111L)

   PMID:27207795

   Open questions at the time

   • In vivo requirement for the enzyme not yet tested by genetic ablation
   • Mechanism linking ROS accumulation to lineage bias not resolved
   • Physiological tetrapyrrole substrate flux unquantified
3. 2020 High

   Knockout mice resolved whether BLVRB is constitutively required versus stress-specific, showing it is dispensable at steady state but cytoprotective during stress hematopoiesis.

   Evidence Blvrb knockout mice with stress hematopoiesis models, multipotential progenitor assays, and lipid peroxidation readouts

   PMID:33359909

   Open questions at the time

   • Molecular trigger that activates BLVRB cytoprotection under stress unknown
   • Link between lipid peroxidation defect and lineage bias not mechanistically dissected
   • Relationship to the human S111L phenotype not directly reconciled
4. 2025 High

   Structural confirmation of the active site and pharmacological inhibition demonstrated that targeting BLVRB enzymatic activity can be exploited to expand platelet production therapeutically.

   Evidence NMR, co-crystallization, inhibitor screening, megakaryocyte differentiation assays, and oral delivery in stress thrombopoiesis mice

   PMID:40216753

   Open questions at the time

   • Selectivity and off-target profile of inhibitors not detailed
   • Whether inhibition phenocopies S111L mechanistically not established
   • Long-term safety of redox enzyme inhibition unaddressed
5. 2025 Medium

   Discovery of an oxygen-sensitive BLVRB–Band 3 complex and a Cys109-mediated trans-nitrosation of GAPDH extended BLVRB function beyond hematopoietic redox control to glycolytic regulation in mature red cells.

   Evidence Deep RBC proteomics, cross-linking interactomics, in vitro S-nitrosation assays, and humanized Band 3 N-terminal truncation mice

   PMID:42224377

   Open questions at the time

   • Trans-nitrosation mechanism relies on in vitro biochemistry without full mutagenesis validation
   • Quantitative contribution to hypoxic glycolytic flux in vivo unclear
   • Reciprocal structural detail of the Band 3 interface not resolved

• How BLVRB's enzymatic redox activity, its Band 3 interaction, and its NO-relay function are integrated into a single physiological program across erythroid and megakaryocyte lineages remains unresolved.
• No unified model linking tetrapyrrole reductase activity to the GAPDH trans-nitrosation function
• Mechanism coupling ROS handling to lineage decision-making unknown
• In vivo significance of the oxygen-sensitive switch for tissue oxygen delivery untested